Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation - PubMed (original) (raw)

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation

M Adams et al. J Clin Invest. 1997.

Abstract

Activation of peroxisome proliferator-activated receptor (PPAR) gamma, a nuclear receptor highly expressed in adipocytes, induces the differentiation of murine preadipocyte cell lines. Recently, thiazolidinediones (TZDs), a novel class of insulin-sensitizing compounds effective in the treatment of non-insulin-dependent diabetes mellitus (NIDDM) have been shown to bind to PPARgamma with high affinity. We have examined the effects of these compounds on the differentiation of human preadipocytes derived from subcutaneous (SC) and omental (Om) fat. Assessed by lipid accumulation, glycerol 3-phosphate dehydrogenase activity, and mRNA levels, subcultured preadipocytes isolated from either SC or Om depots did not differentiate in defined serum-free medium. Addition of TZDs (BRL49653 or troglitazone) or 15-deoxyDelta12,14prostaglandin J2 (a natural PPARgamma ligand) enhanced markedly the differentiation of preadipocytes from SC sites, assessed by all three criteria. The rank order of potency of these agents in inducing differentiation matched their ability to activate transcription via human PPARgamma. In contrast, preadipocytes from Om sites in the same individuals were refractory to TZDs, although PPARgamma was expressed at similar levels in both depots. The mechanism of this depot-specific TZD response is unknown. However, given the association between Om adiposity and NIDDM, the site-specific responsiveness of human preadipocytes to TZDs may be involved in the beneficial effects of these compounds on in vivo insulin sensitivity.

PubMed Disclaimer

Similar articles

• Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.
  Sewter CP, Blows F, Vidal-Puig A, O'Rahilly S. Sewter CP, et al. Diabetes. 2002 Mar;51(3):718-23. doi: 10.2337/diabetes.51.3.718. Diabetes. 2002. PMID: 11872672
• Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro.
  Su JL, Winegar DA, Wisely GB, Sigel CS, Hull-Ryde EA. Su JL, et al. Hybridoma. 1999 Jun;18(3):273-80. doi: 10.1089/027245799315934. Hybridoma. 1999. PMID: 10475242
• Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.
  Digby JE, Montague CT, Sewter CP, Sanders L, Wilkison WO, O'Rahilly S, Prins JB. Digby JE, et al. Diabetes. 1998 Jan;47(1):138-41. doi: 10.2337/diab.47.1.138. Diabetes. 1998. PMID: 9421389
• [Skeletal effects of thiazolidinediones].
  Okazaki R. Okazaki R. Nihon Rinsho. 2000 Feb;58(2):456-60. Nihon Rinsho. 2000. PMID: 10707576 Review. Japanese.
• [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
  Dubois M, Vantyghem MC, Schoonjans K, Pattou F. Dubois M, et al. Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):511-23. Ann Endocrinol (Paris). 2002. PMID: 12527853 Review. French.

Cited by

• Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
  Glesby MJ, Albu J, Chiu YL, Ham K, Engelson E, He Q, Muthukrishnan V, Ginsberg HN, Donovan D, Ernst J, Lesser M, Kotler DP. Glesby MJ, et al. PLoS One. 2013 Apr 12;8(4):e61160. doi: 10.1371/journal.pone.0061160. Print 2013. PLoS One. 2013. PMID: 23593417 Free PMC article. Clinical Trial.
• Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
  Duan SZ, Usher MG, Foley EL 4th, Milstone DS, Brosius FC 3rd, Mortensen RM. Duan SZ, et al. Diabetologia. 2010 Jul;53(7):1493-505. doi: 10.1007/s00125-010-1748-2. Epub 2010 Apr 17. Diabetologia. 2010. PMID: 20401461 Free PMC article.
• The many facets of PPARgamma: novel insights for the skeleton.
  Kawai M, Sousa KM, MacDougald OA, Rosen CJ. Kawai M, et al. Am J Physiol Endocrinol Metab. 2010 Jul;299(1):E3-9. doi: 10.1152/ajpendo.00157.2010. Epub 2010 Apr 20. Am J Physiol Endocrinol Metab. 2010. PMID: 20407009 Free PMC article. Review.
• Adipose depots possess unique developmental gene signatures.
  Yamamoto Y, Gesta S, Lee KY, Tran TT, Saadatirad P, Kahn CR. Yamamoto Y, et al. Obesity (Silver Spring). 2010 May;18(5):872-878. doi: 10.1038/oby.2009.512. Epub 2010 Jan 28. Obesity (Silver Spring). 2010. PMID: 20111017 Free PMC article.
• Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease.
  Chait A, den Hartigh LJ. Chait A, et al. Front Cardiovasc Med. 2020 Feb 25;7:22. doi: 10.3389/fcvm.2020.00022. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32158768 Free PMC article. Review.

References

1. 1. Cell. 1994 Dec 30;79(7):1147-56 - PubMed
2. 1. J Biol Chem. 1994 Dec 9;269(49):31157-61 - PubMed
3. 1. J Biol Chem. 1995 Oct 13;270(41):23975-83 - PubMed
4. 1. Ann Med. 1995 Aug;27(4):435-8 - PubMed
5. 1. Cell. 1995 Dec 1;83(5):803-12 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database